Scheltens, P. et al. Alzheimer’s disease. Lancet 397, 1577–1590 (2021).
Swaddiwudhipong, N. et al. Pre-diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases. Alzheimers Dement. 19, 1752–1763 (2023).
Shah, H. et al. Research priorities to reduce the global burden of dementia by 2025. Lancet Neurol. 15, 1285–1294 (2016).
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77 (2022).
Zetterberg, H. Biofluid-based biomarkers for Alzheimer’s disease-related pathologies: an update and synthesis of the literature. Alzheimers Dement. 18, 1687–1693 (2022).
Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 18, 2669–2686 (2022).
Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034–1042 (2021).
Verberk, I. M. W. et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2, e87–e95 (2021).
Kim, K. et al. Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma. Nat. Commun. 11, 119 (2020).
Ashton, N. J. et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat. Med. 28, 2555–2562 (2022).
Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422–433 (2020).
Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360–369 (2023).
Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400–418 (2022).
Tanaka, T. et al. Plasma proteomic signatures predict dementia and cognitive impairment. Alzheimers Dement. (N Y) 6, e12018 (2020).
Hye, A. et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain 129, 3042–3050 (2006).
Bai, B. et al. Proteomic landscape of Alzheimer’s disease: novel insights into pathogenesis and biomarker discovery. Mol. Neurodegener. 16, 55 (2021).
Walker, K. A. et al. Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat. Aging 1, 473–489 (2021).
Dubois, B. et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484–496 (2021).
de Wolf, F. et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain 143, 1220–1232 (2020).
Ma, W. et al. Elevated levels of serum neurofilament light chain associated with cognitive impairment in vascular dementia. Dis. Markers 2020, 6612871 (2020).
Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471–1483 (2021).
Cicognola, C. et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res. Ther. 13, 68 (2021).
McGrath, E. R. et al. Growth differentiation factor 15 and NT-proBNP as blood-based markers of vascular brain injury and dementia. J. Am. Heart Assoc. 9, e014659 (2020).
Whelan, C. D. et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. Acta Neuropathol. Commun. 7, 169 (2019).
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R. & Mroczko, B. Neurogranin and neuronal pentraxin receptor as synaptic dysfunction biomarkers in Alzheimer’s disease. J. Clin. Med. 10, 4575 (2021).
O’Connor, A. et al. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. J. Neurol. Neurosurg. Psychiatry 94, 90–92 (2023).
Kuhle, J. et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry 86, 273–279 (2015).
Fuchs, T. et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline – the Sydney Memory and Aging Study. Aging Cell 12, 882–889 (2013).
Babu, H. et al. Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy. Front. Immunol. 10, 1965 (2019).
Castellano, J. M. et al. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl Acad. Sci. USA 109, 15502–15507 (2012).
Li, W. et al. Dl-3-n-butylphthalide reduces cognitive impairment induced by chronic cerebral hypoperfusion through GDNF/GFRα1/Ret signaling preventing hippocampal neuron apoptosis. Front. Cell Neurosci. 13, 351 (2019).
Oeckl, P. et al. Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J. Neurol. Neurosurg. Psychiatry 93, 659–667 (2022).
Kivisäkk, P. et al. Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front. Neurol. 14, 1069411 (2023).
Beyer, L. et al. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer’s disease diagnosis within 17 years. Alzheimers Dement. 19, 1020–1028 (2023).
Stocker, H. et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer’s disease risk: results from a prospective cohort followed over 17 years. Alzheimers Dement. 19, 25–35 (2023).
Oeckl, P. et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J. Alzheimers Dis. 67, 481–488 (2019).
Heller, C. et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 263–270 (2020).
Verberk, I. M. W. et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res. Ther. 12, 118 (2020).
Rajan, K. B. et al. Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann. Neurol. 88, 1065–1076 (2020).
Katisko, K. et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J. Neurol. Neurosurg. Psychiatry 92, 1305–1312 (2021).
Katsanos, A. H. et al. Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage. Stroke 48, 2586–2588 (2017).
Undén, J. et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J. Neurol. 256, 72–77 (2009).
Elahi, F. M. et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease. Alzheimers Dement. 16, 681–695 (2020).
Shir, D. et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer’s disease and vascular pathology. Alzheimers Dement. (Amst.) 14, e12291 (2022).
Vermeer, S. E. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215–1222 (2003).
Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat. Rev. Neurol. 11, 157–165 (2015).
Cullen, N. C. et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat. Commun. 12, 3555 (2021).
Fyfe, I. Neurofilament light chain – new potential for prediction and prognosis. Nat. Rev. Neurol. 15, 557 (2019).
Pilotto, A. et al. Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with Lewy bodies. J. Alzheimers Dis. 82, 913–919 (2021).
Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135–140 (2016).
Chai, Y. L. et al. Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. Medicine (Baltimore) 95, e4566 (2016).
Walker, K. A. et al. Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci. Transl. Med. 15, eadf5681 (2023).
Schindowski, K. et al. Regulation of GDF-15, a distant TGF-β superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res. 343, 399–409 (2011).
Andersson, C. et al. Associations of circulating growth differentiation factor-15 and ST2 concentrations with subclinical vascular brain injury and incident stroke. Stroke 46, 2568–2575 (2015).
van Dijk, E. J. et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 39, 2712–2719 (2008).
Conte, M. et al. GDF15, an emerging key player in human aging. Ageing Res. Rev. 75, 101569 (2022).
Wang, D. et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat. Rev. Endocrinol. 17, 592–607 (2021).
Marks, J. D. et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res. Ther. 13, 199 (2021).
Cousins, K. A. Q. et al. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimers Dement. 17, 822–830 (2021).
Illán-Gala, I. et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology 96, e671–e683 (2021).
Jiang, Y. et al. Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer’s disease screening and staging. Alzheimers Dement. 18, 88–102 (2022).
Prince, M. et al. World Alzheimer Report 2015—The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International www.alzint.org/resource/world-alzheimer-report-2015/ (2015).
You, J. et al. Development of a novel dementia risk prediction model in the general population: a large, longitudinal, population-based machine-learning study. EClinicalMedicine 53, 101665 (2022).
Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329–338 (2023).
Dhindsa, R. S. et al. Rare variant associations with plasma protein levels in the UK Biobank. Nature 622, 339–347 (2023).
Wik, L. et al. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol. Cell Proteomics 20, 100168 (2021).
Elliott, P., Peakman, T. C. & UK Biobank The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234–244 (2008).
You, J. et al. Plasma proteomic profiles predict individual future health risk. Nat. Commun. 14, 7817 (2023).
Tynkkynen, J. et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: a prospective study in eight cohorts. Alzheimers Dement. 14, 723–733 (2018).
Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).
Korthauer, K. et al. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118 (2019).
Guolin K. et al. LightGBM: a highly efficient gradient boosting decision tree. In Advances in Neural Information Processing Systems 30 (NIPS 2017) (eds von Luxburg, U., Guyon, I., Bengio, S., Wallach, H. & Fergus, R.) 3149–3157 (Curran Associates Inc., 2017).
DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988).
Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
Fang, F. et al. Lipids, apolipoproteins, and the risk of Parkinson disease. Circ. Res. 125, 643–652 (2019).